Welcome to our dedicated page for Intuitive Surgical news (Ticker: ISRG), a resource for investors and traders seeking the latest updates and insights on Intuitive Surgical stock.
Intuitive Surgical Inc. (NASDAQ: ISRG), the pioneer of robotic-assisted minimally invasive surgery, provides critical updates through this comprehensive news hub. Track the latest developments surrounding the da Vinci Surgical System, regulatory milestones, and strategic initiatives shaping the future of surgical care.
This resource delivers verified press releases and financial updates essential for understanding ISRG's market position. Investors gain insights into earnings reports, partnership announcements, and technology advancements while medical professionals stay informed about clinical applications and procedural innovations.
Key content includes quarterly financial results, FDA clearances for new instruments, global expansion updates, and research collaborations advancing robotic surgery. All materials are sourced from official channels to ensure accuracy and compliance with financial disclosure standards.
Bookmark this page for real-time access to ISRG's evolving role in healthcare technology. Combine strategic awareness with operational knowledge through our curated collection of company-verified information.
Intuitive (Nasdaq: ISRG) announced a proposed three-for-one stock split pending shareholder approval. The Amendment to the Company’s Certificate of Incorporation is set for a vote at the Special Meeting on September 20, 2021. If approved, stockholders of record on September 27, 2021 will receive two additional shares for every share held, with trading expected to start on a split-adjusted basis on October 5, 2021. This move aims to enhance liquidity and accessibility for investors.
Intuitive (Nasdaq: ISRG) reported strong financial results for Q2 2021, with revenues of $1.46 billion, up 72% from $0.85 billion in Q2 2020. This growth is attributed to a 68% increase in da Vinci procedures and a significant rise in system shipments, totaling 328 units—an 84% increase year-over-year. GAAP net income reached $517 million, or $4.25 per diluted share, compared to $68 million a year earlier. The company ended the quarter with $7.7 billion in cash and investments, reflecting solid operational cash generation and recovery from pandemic-related disruptions.
Intuitive (Nasdaq: ISRG) announced the appointment of Dr. Monica P. Reed to its board of directors, effective April 22, 2021. Dr. Reed, a former executive at AdventHealth, has over 30 years of experience in healthcare leadership, including serving as chief medical officer and CEO at AdventHealth. Her extensive background in hospital administration is expected to enhance Intuitive's strategic direction in robotic-assisted surgery. CEO Gary Guthart expressed optimism about her contributions to improving service to surgeons and healthcare systems.
Intuitive (Nasdaq: ISRG) reported strong Q1 2021 results, with revenue reaching $1.29 billion, marking an 18% increase year-over-year. The company shipped 298 da Vinci Surgical Systems, a 26% rise from last year, and achieved an installed base of 6,142 systems, up 8%. GAAP net income also grew to $426 million ($3.51 per diluted share), compared to $314 million ($2.62 per diluted share) in Q1 2020. Instruments and accessories revenue rose 14% to $706 million, driven by a 16% increase in da Vinci procedure volume.
Intuitive (Nasdaq: ISRG) reported Q4 2020 revenue of $1.33 billion, up 4% year-over-year. The company experienced a 6% increase in da Vinci procedures but a 3% drop in system shipments, reflecting COVID-19 disruptions. GAAP net income rose to $365 million ($3.02 per diluted share), compared to $358 million ($2.99 per diluted share) in Q4 2019. Operating expenses included a $25 million contribution to the Intuitive Foundation. The installed base of da Vinci systems grew by 7% to 5,989 systems.
Intuitive (Nasdaq: ISRG) reported preliminary fourth quarter and full year 2020 financial results, revealing a 4% revenue increase to approximately $1.33 billion for Q4, while full year revenue declined 3% to about $4.36 billion. Worldwide da Vinci procedures rose by 6% in Q4 and 1% for the year, despite COVID-19 disruptions. However, surgical system shipments fell to 326 in Q4 2020 from 336 in 2019 and totaled 936 for the year, down from 1,119. Notably, instruments and accessories revenue grew by 11% in Q4, totaling approximately $747 million.
Intuitive Surgical (Nasdaq: ISRG) has launched Intuitive Ventures, a $100 million fund aimed at investing in minimally invasive care innovations. This fund will focus on early-stage companies in digital tools, precision diagnostics, and therapeutic technologies. Julian Nikolchev, President of Intuitive Ventures, emphasizes the goal to enhance the continuum of care. With a leadership team experienced in healthcare investment, Intuitive Ventures aims to leverage industry expertise to drive positive healthcare outcomes.
Intuitive (Nasdaq: ISRG) reported Q3 financial results for 2020, revealing a revenue decline of 4% year-over-year to $1,078 million. The company shipped 195 da Vinci Surgical Systems, a decrease of 29% compared to 2019. Despite challenges from COVID-19, da Vinci procedures increased by 7%, and the installed base grew to 5,865 systems, up 8% from last year. Net income fell to $314 million, or $2.60 per diluted share, down from $397 million, or $3.33 per diluted share in Q3 2019. The company also launched a $100 million fund for healthcare innovations.
Intuitive (Nasdaq: ISRG) reported Q2 2020 revenue of $852 million, down 22% from $1,099 million in Q2 2019, heavily impacted by the COVID-19 pandemic. Worldwide da Vinci procedures declined 19%, and the shipment of da Vinci Surgical Systems fell 35% to 178 units. The installed base of systems grew 9% to 5,764. GAAP net income was $68 million ($0.57/share), down from $318 million ($2.67/share) last year. The company ended the quarter with $6.1 billion in cash and equivalents. Despite challenges, Intuitive launched an 'Extended Use Program' for instruments to improve economic efficacy.
FAQ
What is the current stock price of Intuitive Surgical (ISRG)?
What is the market cap of Intuitive Surgical (ISRG)?
